Rex Bionics PLC REX to exhibit at the Hamlyn Symposium
July 10 2014 - 2:00AM
RNS Non-Regulatory
TIDMRXB
Rex Bionics PLC
10 July 2014
10 July 2014
Rex Bionics plc
("Rex Bionics" or the "Company")
REX to exhibit at the Hamlyn Symposium on Medical Robots
Rex Bionics plc (AIM: RXB), the developer and manufacturer of
REX products: hands-free robotic exoskeletons for use by wheelchair
users, announces that it will be exhibiting at the 7(th) Hamlyn
Symposium on Medical Robots, at the Royal Geographical Society,
London, from July 13(th) to July 15(th) 2014.
The Hamlyn Centre for Robots Surgery was established for
developing safe, effective and accessible technologies that can
reshape the future of healthcare for both developing and developed
countries. Focusing on technological innovation, but with a strong
emphasis on clinical translation and direct patient benefit with a
global impact, the centre is at the forefront of research in
imaging, sensing and robotics for addressing global health
challenges associated with demographic, environment, social and
economic changes.
The Hamlyn Symposium, chaired by Lord Darzi of Denham and
Professor Guang-Zhong Yang, of Imperial College, grew out of the
original Imperial College's Cross Faculty Workshops on Medical
Robotics funded by the Hamlyn Centre for Robotic Surgery and is now
established as an annual international forum for clinicians,
engineers and researchers to exchange ideas and explore new
challenges and opportunities in healthcare technologies.
During the Symposium, REX Bionics' brand ambassador, Sophie
Morgan, will demonstrate the benefits of REX for wheelchair users,
in addition to highlighting the applicability to REX as a tool for
researchers & engineers.
Jeremy Curnock Cook, Chief Executive of Rex Bionics, commented:
"The Hamlyn Symposium is at the forefront of collaboration between
those at the cutting edge of technology design for medical robots
and Rex Bionics is delighted to have the opportunity to showcase
REX at this event.
"As REX launches in Europe, we welcome the opportunity to
demonstrate the unique hands-free exoskeleton to such a prestigious
audience."
---
For further information please contact:
Rex Bionics Plc
Jeremy Curnock Cook, Chief Executive Officer
+44 (0) 781 086 6386
Peter Worrall, Chief Financial Officer
+44 (0)1428 645416
Oriel Securities Limited (NOMAD and Broker)
Juliet Thompson/Jonathan Senior
+44 (0) 20 7710 7600
Consilium Strategic Communications
Mary-Jane Elliott / Emma Thompson / Jessica Hodgson / Lindsey
Neville
rexbionics@consilium-comms.com
+44 (0) 203 709 5700
About Rex Bionics
Rex Bionics (AIM: RXB) is an AIM-listed developer and
manufacturer of REX products, hands-free robotic exoskeletons for
use by people with mobility impairments. Founded in Auckland, New
Zealand by two robotics engineers with first-hand experience of
wheelchair users and their needs, Rex Bionics focuses on products
designed to enable wheelchair users to stand and walk autonomously
without the need for crutches or supports and is the only company
to produce hands-free walking devices for wheelchair users. Rex
Bionics' marketed products: REX Rehab and REX Personal, can be used
by people with complete spinal cord injury, but also by a much
broader potential customer base, including people with multiple
sclerosis and muscular dystrophy. In May 2014, Rex Bionics joined
AIM with a fundraising of GBP10 million (gross) to scale up
production, distribution and marketing internationally, in order to
support growing demand for both REX products as well as developing
the next generation of REX devices, REX 3.
For more information please visit, www.rexbionics.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRASSUFLUFLSEEW
Rex Bionics (LSE:RXB)
Historical Stock Chart
From Jun 2024 to Jul 2024
Rex Bionics (LSE:RXB)
Historical Stock Chart
From Jul 2023 to Jul 2024